Clinical Trial Detail

NCT ID NCT02412722
Title Safety, Tolerability, and Pharmacokinetics of MLN0128 as a Single Agent and in Combination With Paclitaxel in Adults With Advanced Nonhematologic Malignancies
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements no
Sponsors Millennium Pharmaceuticals, Inc.
Indications

Advanced Solid Tumor

Therapies

Sapanisertib

Paclitaxel

Age Groups: adult

No variant requirements are available.